Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $53.50 Consensus Price Target from Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given an average recommendation of “Buy” by the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $53.50.

Several analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Scotiabank started coverage on shares of Arcturus Therapeutics in a research report on Wednesday, May 28th. They issued a “sector outperform” rating and a $32.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Canaccord Genuity Group decreased their target price on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Finally, Citigroup restated a “buy” rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th.

Arcturus Therapeutics Stock Down 0.5%

ARCT stock opened at $12.29 on Wednesday. The company’s 50 day simple moving average is $12.05 and its 200-day simple moving average is $14.26. The firm has a market capitalization of $333.30 million, a PE ratio of -4.86 and a beta of 2.30. Arcturus Therapeutics has a 12 month low of $8.04 and a 12 month high of $28.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.64.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($1.58) by $1.06. The business had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. Equities analysts expect that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Byrne Asset Management LLC boosted its holdings in shares of Arcturus Therapeutics by 89.8% in the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 1,365 shares during the last quarter. US Bancorp DE boosted its holdings in shares of Arcturus Therapeutics by 218.9% in the 1st quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,329 shares during the last quarter. Virtus ETF Advisers LLC boosted its holdings in shares of Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Arcturus Therapeutics in the 4th quarter valued at $71,000. Finally, Strs Ohio acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at $89,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.